Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$34.37M$34.37Mderived+107.7% vs Q4 2021 Net Income-$66.18M-$66.18MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$66,151,000N/M Operating Cash Flowderived-$52,513,000N/M Free Cash Flowderived-$52,846,000N/M Margins · derivedOperating margin-192.5%+625.0 pt vs Q4 2021
Net margin-192.6%+617.9 pt vs Q4 2021
ended Dec 31, 2022 · filed Feb 27, 2023 · 58 d after period end